Company news

Kodiak Sciences Inc news in 2026

Kodiak Sciences Inc's news releases, calls and decks from 2026, newest first.

View company

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

October 7, 2026

Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.

September 28, 2026

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

September 25, 2026

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

August 13, 2026

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

August 10, 2026

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

August 6, 2026

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

May 28, 2026

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

May 7, 2026

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

May 1, 2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

March 30, 2026

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

March 25, 2026

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

February 3, 2026

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Decks in 2026